表紙
市場調查報告書
商品編碼
365784

整合素β3:開發中產品分析

Integrin Beta 3 - Pipeline Review, H2 2019

出版日期: | 出版商: Global Markets Direct | 英文 74 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供以整合素β3為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,加上企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

整合素β3 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Merck & Co., Inc.
  • SciFluor Life Sciences, LLC
  • Tissue Therapies Limited
  • TWi Pharmaceuticals, Inc.
  • Vascular Pharmaceuticals, Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC1941TDB

Summary:

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) pipeline Target constitutes close to 24 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The latest report Integrin Beta 3 - Pipeline Review, H2 2019, outlays comprehensive information on the Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Integrin beta-3 (B3) or CD61 is a protein that in humans is encoded by the ITGB3 gene. Integrin beta 3 is found along with the alpha IIb chain in platelets. It is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Activation of integrin alpha-IIb/beta-3 leads to platelet interaction through binding of soluble fibrinogen. This leads to rapid platelet aggregation which physically plugs ruptured endothelial surface.

The molecules developed by companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 2, 1 and 15 respectively. Similarly, the universities portfolio in Preclinical stages comprises 5 molecules, respectively. Report covers products from therapy areas Oncology, Ophthalmology, Cardiovascular, Metabolic Disorders, Dermatology, Gastrointestinal, Infectious Disease, Central Nervous System and Immunology which include indications Wet (Neovascular / Exudative) Macular Degeneration, Breast Cancer, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Diabetic Macular Edema, Glioblastoma Multiforme (GBM), Metastatic Melanoma, Pancreatic Cancer, Persistent Corneal Epithelial Defects, Wounds, Diabetic Nephropathy, Diabetic Retinopathy, Escherichia Coli Septicaemia, Ischemic Stroke, Liver Cancer, Lung Cancer, Malabsorption Syndrome, Melanoma, Multiple Myeloma (Kahler Disease), Myocardial Infarction, Primary Sclerosing Cholangitis, Prostate Cancer, Relapsing Multiple Sclerosis (RMS), Rheumatoid Arthritis, Sepsis, Staphylococcus Aureus Septicaemia and Triple-Negative Breast Cancer (TNBC).

Furthermore, this report also reviews key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)
  • The report reviews Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
    • Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Overview
    • Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Companies Involved in Therapeutics Development
    • Acorda Therapeutics Inc
    • BrightGene Bio-Medical Technology Co Ltd
    • Celltrion Inc
    • Factor Therapeutics Ltd
    • Merck & Co Inc
    • Pliant Therapeutics Inc
    • SciFluor Life Sciences LLC
    • Tasly Pharmaceutical Group Co Ltd
    • Virtual Drug Development Inc
  • Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Drug Profiles
    • A-11 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BGC-0222 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-16Y - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cilengitide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cilengitide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Fusion Protein to Antagonize Integrin Alpha V Beta 3 and Integrin Alpha 5 Beta 1 for Rheumatoid Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Fusion Protein to Antagonize ITGA5 and ITGB3 for Ischemic Stroke - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MK-0429 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MSP-68 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NOD-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OCU-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptides to Antagonize Alpha-V Beta-3 Integrin Receptor for Metastatic Melanoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PLN-1177 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Proagio - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Protein to Agonize Integrin Alpha V, Beta 3 and Beta 5 for Malabsorption Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Antagonize VEGFR2, ITGB3 and ITGAV for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rHIgM-22 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RSF-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RUC-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SF-0166 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tetraiodothyroacetic acid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VF-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VF-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • xemilofiban - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Dormant Products
  • Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Discontinued Products
  • Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Acorda Therapeutics Inc, H2 2019
  • Pipeline by BrightGene Bio-Medical Technology Co Ltd, H2 2019
  • Pipeline by Celltrion Inc, H2 2019
  • Pipeline by Factor Therapeutics Ltd, H2 2019
  • Pipeline by Merck & Co Inc, H2 2019
  • Pipeline by Pliant Therapeutics Inc, H2 2019
  • Pipeline by SciFluor Life Sciences LLC, H2 2019
  • Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2019
  • Pipeline by Virtual Drug Development Inc, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Dormant Products, H2 2019 (Contd..2), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019